查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2103726

成人血紅素病檢測市場：全球市場預測（2026-2032 年）

Adult Hemoglobinopathy Testing Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，成人血紅素疾病檢測市場將成長至 39.2 億美元，複合年成長率為 6.00%。

主要市場統計數據
基準年（2025 年） 26億美元
預計年份（2026年） 27.5億美元
預測年份（2032年） 39.2億美元
複合年成長率（） 6.00%

成人血紅素病檢測：執行摘要

成人血紅素病檢測是現代血液學、公共衛生篩檢、生育計畫、輸血醫學和診斷檢測的關鍵支柱。目前的檢測重點在於識別鐮狀細胞疾病、鐮狀細胞表現型、BETA-地中海貧血、α-地中海貧血、血紅蛋白C、血紅蛋白E以及其他可能影響成人健康結果、妊娠管理、祖先風險評估和治療策略決策的結構性血紅蛋白變異。這種需求的促進因素包括血紅蛋白疾病帶來的終身臨床負擔、全球移民趨勢、帶因者檢出率的提高以及成人貧血病因鑑別診斷需求的日益成長。核心檢測方法包括血液常規檢查及紅血球指標、血紅素電泳、高效液相層析、毛細管電泳、等電聚焦、溶解度試驗及確證分子遺傳學檢測。這些檢測對成人尤其重要。這是因為未確診的帶因者狀態和臨床症狀輕微的突變會影響生育計劃、手術全期護理、輸血策略、糖化血紅蛋白（HbA1c）解讀以及接受疾病修正治療或根治性治療的合格。隨著醫療保健系統優先考慮早期檢測、更準確的風險分層和標準化的診斷流程，成人血紅蛋白病檢測正從一項小眾的血液學服務發展成為涵蓋基層醫療、產科、血液學、臨床遺傳學和公共衛生項目的綜合診斷工作流程。

成人血紅素病檢測領域的一次根本性變化。

成人血紅蛋白疾病檢測正經歷著從基於症狀的診斷轉向基於預防和風險的篩檢以及利用數位技術解讀檢測結果的結構性轉變。傳統上，許多成年人只有在出現不明原因的貧血、紅血球數異常、妊娠相關評估或家族病史時才會接受檢測。如今，檢測擴大融入產前諮詢、產前護理、移民健康評估、捐血篩檢和慢性病管理。這種轉變源自於臨床上日益增強的認知，即血紅蛋白變異會干擾糖化血紅蛋白（HbA1c）的測量，使貧血檢測複雜化，並影響鐮狀細胞疾病和地中海貧血症候群的治療策略。檢查室技術的革新也在加速。雖然高效液相層析（HPLC）和毛細管電泳仍是廣泛應用的一線檢測平台，但分子診斷在闡明複雜基因型、檢測α-珠蛋白缺失、識別罕見突變以及支持生殖風險評估方面正變得越來越重要。同時，檢查室正在推進報告標準化、反射性檢測流程規範、品質保證以及與電子健康記錄的互通性。因此，一個更完善的診斷生態系統正在構建，成人血紅蛋白病檢測正在支持預防醫學、精準醫學以及為遺傳性血紅蛋白病高風險人群提供公平的醫療服務。

人工智慧對血紅素疾病診斷的累積影響

人工智慧正透過改善模式識別、簡化工作流程、提供決策支援和進行人群層面的風險識別，開始影響成人血紅素病檢測。在診斷檢查室中，人工智慧工具可輔助解讀複雜的色譜圖、電泳圖、血液常規檢查模式和多參數血液學數據，從而幫助識別與地中海貧血攜帶者、鐮狀細胞突變、混合型血紅蛋白病或可能伴有遺傳性疾病的缺鐵性貧血相符的特徵。人工智慧還可以透過整合紅血球指標、血紅素組成數據、臨床背景、與種族無關的風險指標、家族病史和先前檢測結果，增強反射性檢測的邏輯性。在醫療保健系統中，機器學習技術可以幫助識別傳統篩檢遺漏的成人患者，例如復發性小細胞性貧血、不明原因貧血、妊娠風險指標異常或糖化血紅蛋白（HbA1c）檢測結果不一致的患者。其累積目的並非取代臨床專家，而是增強標準化、及時性和可重複性的決策。負責任的實施需要高度透明的演算法、在不同祖先群體中檢驗、偏差監測、檢查室自研檢測的管治、資料隱私保護以及臨床醫生的監督。如果實施得當，人工智慧可以減少診斷延誤、提高報告一致性、最佳化確診性基因檢測的使用，並支持更公平的成人血紅蛋白病篩檢途徑。

成人血紅素病檢測的區域分析

亞太地區對成人血紅蛋白疾病檢測至關重要。這是因為血紅蛋白E、BETA-地中海貧血、α-地中海貧血和其他遺傳性紅血球疾病在南亞、東南亞和中國部分地區廣泛流行。產前篩檢、帶因者檢測、分子診斷確診檢測以及與移民相關的檢測的普及，使得疾病負擔沉重且醫療資源充足的醫療系統都面臨著檢測需求。歐洲擁有成熟的檢查室標準、完善的產前篩檢體系，以及與移民相關的檢測需求，尤其是在非洲、地中海、中東和亞裔人口中。北美擁有完善的新生兒篩檢基礎設施、成人鐮狀細胞病診療網路、產前帶因者篩檢和充足的檢查室資源，但對於移民、育齡成年人以及出現不明原因貧血或糖化血紅蛋白（HbA1c）不匹配的患者而言，成人檢測的重要性日益凸顯。在拉丁美洲，人們越來越關注鐮狀細胞疾病和地中海貧血的攜帶者狀態，巴西和墨西哥尤其重視公共衛生項目，關注具有不同祖先背景的人群，並致力於改善診斷途徑。非洲仍然是全球單紅蛋白疾病負擔的中心，特別是鐮狀細胞疾病，鐮狀檢測需求與漏診、成年存活率、血液安全、生殖諮詢以及加強檢測能力密切相關。在中東，遺傳性單紅蛋白疾病的負擔沉重，婚前篩檢、計劃生育措施以及針對鐮狀細胞疾病和鐮狀的確診基因檢測為應對這一問題提供了支持。在所有地區，成人早期檢測、提高基因型與表現型的相關性、改善諮詢服務以及向綜合護理路徑的轉變都是關鍵趨勢。

主要集團分析：北約、七國集團、金磚國家、歐盟、東協、海灣合作理事會

在北約成員國中，北美和歐洲高所得國家的檢測基礎設施加強了成人血紅素病的檢測。在這些地區，軍事戰備、輸血安全、移民健康和生殖諮詢等因素都為準確檢測成人血紅素變異體提供了支持。七國集團（G7）國家通常擁有先進的診斷檢測網路、臨床指南、保險報銷機制和基因檢測資源，從而支持在基層醫療、產科和血液科開展全面的成人血紅蛋白病檢測。金磚國家（BRICS）涵蓋了患者負擔沉重且醫療體系發達的地區；印度、中國、巴西和南非在鐮狀貧血、地中海貧血、基因帶原檢測和公共衛生篩檢方面尤為重要，而俄羅斯的作用則更多地與專科血液學和區域移民模式相關。歐盟（EU）強調檢查室品質標準化、跨境醫療協調、產前風險評估以及為血紅蛋白病高風險移民和少數族裔提供公平的醫療服務。在東協地區，成人血紅素病檢測受到多個成員國α-地中海貧血、BETA-地中海貧血和血紅蛋白E高發生率的顯著影響，因此攜帶者篩檢、產前檢測以及透過分子診斷進行的確診檢測尤為重要。在海灣合作理事會（GCC）地區，由於不斷完善的遺傳基礎設施和諮詢服務，長期以來致力於透過婚前和孕前篩檢計畫預防鐮狀細胞疾病和地中海貧血。在全部區域，檢測策略受到遺傳疾病負擔、篩檢政策、醫療保健系統資金籌措、遺傳諮詢服務的可及性以及將檢測結果與長期成人護理相結合的能力等因素的影響。

各國成人血紅蛋白疾病檢測的分析。

中國，特別是南方省份，面臨嚴重的α-BETA-地中海貧血負擔，並持續重視婚前、產前和基因檢測。美國在成人血紅蛋白疾病檢測方面擁有廣泛的能力，這得益於其新生兒篩檢的歷史、血液學網路、鐮狀攜帶者篩檢，以及對鐮狀細胞表現型、地中海貧血表現型和影響HbA1c解讀的血紅蛋白突變成人患者的持續需求。日本儘管人群患病率較低，但由於罕見突變、國際病例和專業的血液學領域，仍然保持著高品質的診斷能力。印度的成人血紅蛋白病譜系最為複雜，包括BETA-地中海貧血、鐮狀細胞病、東北地區的血紅蛋白E，以及區域集中的土著和社區特異性風險，因此攜帶者篩檢和成人診斷至關重要。德國、英國、法國、義大利和西班牙將先進的檢測基礎設施與源自地中海、非洲、中東和亞洲血統人群的檢測需求相結合。在英國，系統性的產前和新生兒篩檢計畫得以維持；而在義大利和西班牙，地中海貧血攜帶者和地中海血紅蛋白變異體的檢測尤其重要。澳洲的檢測需求主要受其多元文化人口、產前篩檢、移民健康和原住民健康問題的影響。儘管韓國的盛行率相對較低，但由於移民、生殖篩檢和先進的分子診斷技術，其檢測需求日益成長。加拿大將全民健保與針對不同移民群體的檢測和生殖諮詢結合。俄羅斯的成人檢測系統取決於專業檢查室的能力、區域轉診途徑以及與移民相關的病例的發現。巴西和墨西哥在鐮狀細胞疾病和地中海貧血的臨床檢測方面面臨著巨大的需求，尤其是在巴西，非洲裔人口的健康優先事項以及公眾對鐮狀細胞疾病日益成長的關注是主要促成因素。當我們把這些國家的具體趨勢放在一起考慮時，我們可以看出，成人血紅蛋白病檢測不再局限於歷史上患病率較高的人群，而是擴大融入全球化、以精準為導向的醫療保健系統中。

為行業領導者提供的實用建議

產業領導者應優先考慮整合診斷路徑，透過清晰的反射演算法，將血液學指標、血紅蛋白組分分析和確診分子檢測相結合。實驗室和醫療保健提供者必須規範結果解讀，確保特異性突變進行報告，並明確告知與合併缺鐵、近期輸血、妊娠和糖化血紅蛋白（HbA1c）干擾相關的局限性。投資遺傳諮詢系統至關重要，尤其對於有生育患有臨床顯著血紅蛋白疾病兒童風險的成年人和育齡夫婦而言。醫療保健系統應利用電子健康記錄中的觸發因素，例如不明原因的小細胞性貧血、持續性貧血、家族病史、高風險妊娠指標和血糖指標不穩定等，來擴展成人病例發現策略。診斷設備製造商和服務提供者應專注於分析準確性、自動化、檢體到結果的效率、互通性以及檢驗的人工智慧輔助決策支援。公共衛生相關人員應根據當地流行病學情況調整篩檢方案，避免僅基於祖源資訊進行假設，以免在日益多元化的人群中遺漏病例。領導者還應加強品質保證、臨床醫生教育、資料隱私保護以及確保患者公平獲得確診檢測，尤其是在醫療服務不足或疾病負擔沉重的地區。最有效的策略是將檢測與具體的醫療服務相結合，例如生殖諮詢、轉診至血液科專家、輸血計劃、預防性管理和長期監測。

分析方法

本報告採用資訊來源（例如同行檢驗的醫學文獻、世界衛生組織、國家篩檢指南、血液學會建議、實驗室標準和公共衛生計畫文件）的已驗證的臨床、公共衛生、臨床檢驗醫學和流行病學證據的二手研究方法撰寫而成。調查方法從診斷方法、應用案例、區域疾病負擔、篩檢政策、醫療保健系統能力和新興技術應用等角度考察了成人血紅蛋白病檢測。證據經過仔細審查，以確定其與成人檢測的相關性，包括攜帶者檢測、鐮狀細胞病診斷、地中海貧血評估、血紅蛋白變異體識別、產前和孕前工作流程、對糖化血紅蛋白（HbA1c）的干擾以及確診性分子檢測。區域和國家層面的具體見解被定性地整合，以反映已知的疾病分佈、人口遷移趨勢、檢測實驗室的可及性、公共衛生基礎設施和臨床實踐模式。本報告未包含市場規模、市佔率或預測假設。本報告的分析方法強調數據驅動的解釋、多資訊來源的檢驗、臨床有效性，以及對已確立的證據和新興趨勢（如人工智慧驅動的診斷決策支援）的仔細區分。

結論

隨著醫療保健系統向預防性診斷、降低生殖風險、精準血液學以及公平管理遺傳性血液疾病的方向轉變，成人血紅蛋白病檢測的重要性日益凸顯。該領域正從單一的電泳或層析法結果發展到整合紅血球指標、血紅蛋白組分分析、基因檢測、數位化報告和臨床決策支援的綜合工作流程。不同地區的需求差異顯著；亞太地區和中東及非洲面臨著沉重的遺傳性疾病負擔，而北美、歐洲、拉丁美洲和大洋洲則日益需要針對移民和具有不同祖先背景的人群進行相關檢測。人工智慧在經過負責任的檢驗後，可以提高病例發現率、報告一致性和檢查室效率，但它必須牢固地建立在臨床管治和跨人群檢驗的基礎上。行業領導者的首要任務是提供準確、便捷且可操作的成人血紅蛋白疾病檢測，並將診斷與諮詢、護理路徑和長期預後聯繫起來。最大的機會在於標準化演算法、分子層級驗證、可互通的數據系統以及全面的篩檢策略，這些策略將血紅蛋白疾病風險視為全球健康問題，而不是特定地區的疾病。

目錄

第1章 引言

第2章 分析方法

  • 分析設計
  • 分析框架
  • 市場規模預測
  • 數據三角測量
  • 分析結果
  • 分析的前提條件
  • 分析的局限性

第3章執行摘要

  • 首席體驗長的觀點
  • 市場規模和成長趨勢
  • 市佔率分析（2025 年）
  • FPNV定位矩陣（2025）
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入（GTM）策略

第5章 市場洞察

  • 消費者分析與最終用戶觀點
  • 消費者體驗基準測試
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 成本效益分析（ROI）和成本效益分析（CBA）

第6章：人工智慧（AI）的累積影響（2026 年）

第7章 成人血紅素疾病檢測市場：依檢測方式分類

  • 檢查室檢測
    • 電泳
    • 基因分析
    • 高效液相層析
  • PoC測試

第8章：成人血紅素疾病檢測市場：依疾病類型分類

  • 血紅素C病
  • 鐮狀細胞貧血症
  • 地中海型貧血
    • α-地中海貧血
    • BETA-地中海型貧血
    • δ-地中海貧血

第9章：成人血紅素疾病檢測市場：依通路分類

  • 線上
  • 離線

第10章：成人血紅素疾病檢測市場：依最終用戶分類

  • 診斷檢查室
    • 醫院檢查室
    • 獨立檢測實驗室
    • 參考檢查室
  • 醫院
    • 二級醫療醫院
    • 三級醫療醫院
  • 研究機構

第11章：成人血紅素疾病檢測市場：依地區分類

  • 亞太地區
  • 歐洲
  • 北美洲
  • 拉丁美洲
  • 非洲
  • 中東

第12章 成人血紅素疾病檢測市場：依組別分類

  • NATO
  • G7
  • BRICS
  • EU
  • ASEAN
  • GCC

第13章：成人血紅素疾病檢測市場：依國家分類

  • 中國
  • 美國
  • 日本
  • 印度
  • 德國
  • 英國
  • 澳洲
  • 法國
  • 韓國
  • 義大利
  • 加拿大
  • 俄羅斯
  • 巴西
  • 墨西哥
  • 西班牙

第14章 競爭格局

  • 市佔率分析（2025 年）
  • FPNV定位矩陣（2025）
  • 市場集中度分析（2025 年）
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析（2025 年）
  • 產品系列分析（2025 年）
  • 基準分析（2025 年）

第15章：公司簡介

  • ARKRAY, Inc.
  • Beckman Coulter, Inc.
  • Bio-Rad Laboratories, Inc.
  • Bluebird Bio, Inc.
  • Creative Diagnostics
  • F. Hoffmann-La Roche Ltd.
  • HORIBA Group
  • Illumina, Inc.
  • Laboratory Corporation of America Holdings
  • Merck KGaA
  • PerkinElmer, Inc.
  • Quest Diagnostics Incorporated
  • Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
  • Shimadzu Corporation
  • Siemens Healthineers AG
  • Sysmex Europe SE
  • Thermo Fisher Scientific Inc.
  • Tosoh Corporation
  • Trinity Biotech PLC
Product Code: MRR-C002B1C99763

The Adult Hemoglobinopathy Testing Market is projected to grow by USD 3.92 billion at a CAGR of 6.00% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 2.60 billion
Estimated Year [2026] USD 2.75 billion
Forecast Year [2032] USD 3.92 billion
CAGR (%) 6.00%

Adult Hemoglobinopathy Testing: Executive Summary

Adult hemoglobinopathy testing is a critical pillar of modern hematology, public health screening, reproductive planning, transfusion medicine, and precision diagnostics. The testing landscape focuses on identifying inherited hemoglobin disorders such as sickle cell disease, sickle cell trait, beta-thalassemia, alpha-thalassemia, hemoglobin C, hemoglobin E, and other structural hemoglobin variants that may affect adult health outcomes, pregnancy management, ancestry-informed risk assessment, and treatment decisions. Demand is supported by the lifelong clinical burden of hemoglobinopathies, global migration patterns, expanded carrier detection, and the increasing need to differentiate anemia causes in adult populations. Core laboratory methods include complete blood count with red cell indices, hemoglobin electrophoresis, high-performance liquid chromatography, capillary electrophoresis, isoelectric focusing, solubility testing, and confirmatory molecular genetic testing. In adults, testing is especially important because undiagnosed carrier states or clinically mild variants can influence family planning, perioperative care, transfusion strategy, interpretation of HbA1c, and eligibility for disease-modifying or curative therapies. As healthcare systems prioritize earlier detection, better risk stratification, and standardized diagnostic pathways, adult hemoglobinopathy testing is evolving from a niche hematology service into an integrated diagnostic workflow spanning primary care, obstetrics, hematology, clinical genetics, and population health programs.

Transformative Shifts in the Adult Hemoglobinopathy Testing Landscape

The adult hemoglobinopathy testing landscape is undergoing a structural shift from symptom-driven diagnosis to proactive, risk-based screening and digitally enabled laboratory interpretation. Historically, many adults were tested only after unexplained anemia, abnormal red cell indices, pregnancy-related evaluation, or family history prompted investigation. Today, testing is increasingly embedded in preconception counseling, antenatal pathways, migrant health assessments, blood donor screening, and chronic disease management. This shift is reinforced by greater clinical awareness that hemoglobin variants can interfere with HbA1c measurement, complicate anemia workups, and affect therapeutic decisions for sickle cell disease and thalassemia syndromes. Laboratory transformation is also accelerating. High-performance liquid chromatography and capillary electrophoresis continue to serve as widely used front-line platforms, while molecular diagnostics are becoming more important for resolving complex genotypes, detecting alpha-globin deletions, identifying rare variants, and supporting reproductive risk assessment. At the same time, laboratories are pursuing harmonized reporting, reflex testing algorithms, quality assurance, and interoperability with electronic health records. The result is a more connected diagnostic ecosystem where adult hemoglobinopathy testing supports preventive care, precision medicine, and equitable access for populations with elevated inherited hemoglobin disorder risk.

Cumulative Impact of Artificial Intelligence on Hemoglobinopathy Diagnostics

Artificial intelligence is beginning to influence adult hemoglobinopathy testing by improving pattern recognition, workflow efficiency, decision support, and population-level risk identification. In diagnostic laboratories, AI-enabled tools can support interpretation of complex chromatograms, electropherograms, complete blood count patterns, and multi-parameter hematology data, helping flag profiles consistent with thalassemia trait, sickle variants, mixed hemoglobinopathies, or possible iron deficiency coexisting with inherited disorders. AI can also strengthen reflex testing logic by integrating red cell indices, hemoglobin fraction data, clinical context, ethnicity-independent risk indicators, family history, and prior results. In health systems, machine learning approaches may help identify adults who were missed by earlier screening, including individuals with recurrent microcytosis, unexplained anemia, pregnancy risk indicators, or inconsistent HbA1c results. The cumulative impact is not the replacement of clinical expertise but the amplification of standardized, timely, and reproducible decision-making. Responsible adoption requires transparent algorithms, validation across diverse ancestries, bias monitoring, laboratory-developed test governance, data privacy safeguards, and clinician oversight. When deployed appropriately, artificial intelligence can reduce diagnostic delays, improve reporting consistency, optimize confirmatory genetic testing utilization, and support more equitable adult hemoglobinopathy screening pathways.

Key Regional Insights for Adult Hemoglobinopathy Testing

Asia-Pacific represents a highly important region for adult hemoglobinopathy testing because hemoglobin E, beta-thalassemia, alpha-thalassemia, and other inherited red cell disorders are prevalent across South Asia, Southeast Asia, and parts of China. Expanded antenatal screening, carrier detection, molecular confirmation, and migration-linked testing are shaping demand across both high-burden and high-capacity health systems. Europe has mature laboratory standards, prenatal screening initiatives, and migration-driven testing needs, particularly for populations with ancestry from Africa, the Mediterranean, the Middle East, and Asia. North America is characterized by established newborn screening infrastructure, adult sickle cell disease care networks, prenatal carrier screening, and strong laboratory access, while adult testing is increasingly relevant for immigrants, reproductive-age adults, and patients with unexplained anemia or HbA1c discordance. Latin America shows growing attention to sickle cell disease and thalassemia traits, with Brazil and Mexico emphasizing public health programs, ancestry-diverse populations, and improved diagnostic access. Africa remains central to the global hemoglobinopathy burden, particularly for sickle cell disease, with adult testing needs linked to underdiagnosis, survival into adulthood, blood safety, reproductive counseling, and strengthening of laboratory capacity. The Middle East has a substantial inherited hemoglobinopathy burden, supported by premarital screening, family planning initiatives, and confirmatory genetic testing for sickle cell disease and thalassemia. Across all regions, the central trend is movement toward earlier adult identification, better genotype-phenotype correlation, improved counseling, and integrated care pathways.

Key Group Insights Across NATO, G7, BRICS, EU, ASEAN, and GCC

Across NATO countries, adult hemoglobinopathy testing is reinforced by high-income laboratory systems in North America and Europe, where military readiness, transfusion safety, immigrant health, and reproductive counseling support accurate adult hemoglobin variant detection. G7 countries tend to have advanced diagnostic laboratory networks, clinical guidelines, reimbursement pathways, and genetic testing availability, supporting comprehensive adult hemoglobinopathy testing in primary care, obstetrics, and hematology. BRICS countries collectively include both high-burden and high-capacity settings, with India, China, Brazil, and South Africa particularly relevant to sickle cell disease, thalassemia, carrier detection, and public health screening, while Russia's role is more linked to specialized hematology and regional migration patterns. The European Union emphasizes standardized laboratory quality, cross-border healthcare coordination, prenatal risk assessment, and equitable access for migrant and minority populations with elevated hemoglobinopathy risk. Within ASEAN, adult hemoglobinopathy testing is strongly shaped by the high frequency of alpha-thalassemia, beta-thalassemia, and hemoglobin E across several member states, making carrier screening, antenatal testing, and molecular confirmation especially relevant. The GCC has a long-standing focus on sickle cell disease and thalassemia prevention through premarital and preconception screening programs, supported by expanding genetics infrastructure and counseling services. Across these groups, testing strategies are influenced by inherited disease burden, screening policy, health system financing, genetic counseling availability, and the ability to connect laboratory results with long-term adult care.

Key Country Insights for Adult Hemoglobinopathy Testing

China faces significant alpha- and beta-thalassemia burdens in southern provinces and continues to emphasize premarital, prenatal, and genetic testing approaches. The United States has broad adult hemoglobinopathy testing capabilities supported by newborn screening history, hematology networks, prenatal carrier screening, and ongoing needs among adults with sickle cell disease, sickle cell trait, thalassemia traits, and hemoglobin variants that affect HbA1c interpretation. Japan has lower population prevalence but maintains high-quality diagnostic capacity for rare variants, imported cases, and specialized hematology. India has one of the most complex adult hemoglobinopathy profiles, including beta-thalassemia, sickle cell disease, hemoglobin E in the northeast, and regionally concentrated tribal and community risks, making carrier detection and adult diagnosis essential. Germany, the United Kingdom, France, Italy, and Spain combine advanced laboratory infrastructure with Mediterranean, African, Middle Eastern, and Asian ancestry-linked testing needs; the United Kingdom maintains structured antenatal and newborn screening programs, while Italy and Spain are especially relevant for thalassemia traits and Mediterranean hemoglobin variants. Australia's testing needs are driven by multicultural demographics, antenatal screening, migrant health, and indigenous health considerations. South Korea has comparatively lower endemic prevalence but rising relevance through immigration, reproductive screening, and advanced molecular diagnostics. Canada combines universal healthcare access with targeted testing for diverse immigrant populations and reproductive counseling. Russia's adult testing environment is shaped by specialized laboratory capacity, regional referral pathways, and migration-linked case detection. Brazil and Mexico face clinically important sickle cell and thalassemia testing needs, with Brazil particularly influenced by Afro-descendant population health priorities and expanded public health attention to sickle cell disease. Together, these country-level dynamics show that adult hemoglobinopathy testing is no longer confined to historically high-prevalence populations; it is increasingly embedded in globalized, precision-oriented healthcare systems.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize integrated diagnostic pathways that combine hematology indices, hemoglobin fraction analysis, and confirmatory molecular testing through clear reflex algorithms. Laboratories and healthcare providers should standardize result interpretation, ensure variant-specific reporting, and clearly communicate limitations related to coexisting iron deficiency, recent transfusion, pregnancy, and HbA1c interference. Investment in genetic counseling capacity is essential, particularly for reproductive-age adults and couples at risk of having children with clinically significant hemoglobin disorders. Health systems should expand adult case-finding strategies by using electronic health record triggers for unexplained microcytosis, persistent anemia, family history, high-risk pregnancy indicators, and discordant glycemic markers. Diagnostic manufacturers and service providers should focus on analytical accuracy, automation, sample-to-answer efficiency, interoperability, and validated AI-assisted decision support. Public health stakeholders should align screening programs with local epidemiology while avoiding ancestry-only assumptions that can miss cases in increasingly diverse populations. Leaders should also strengthen quality assurance, clinician education, data privacy, and equitable access to confirmatory testing, especially in underserved and high-burden regions. The most effective strategies will connect testing with actionable care, including reproductive counseling, hematology referral, transfusion planning, preventive management, and long-term monitoring.

Research Methodology

This executive summary is structured using a secondary research methodology grounded in verified clinical, public health, laboratory medicine, and epidemiological evidence from authoritative sources such as peer-reviewed medical literature, international health agencies, national screening guidelines, hematology society recommendations, laboratory standards, and public health program documentation. The analysis considers adult hemoglobinopathy testing across diagnostic modalities, clinical use cases, regional disease burden, screening policy, health system capacity, and emerging technology adoption. Evidence was reviewed for relevance to adult testing, including carrier detection, sickle cell disease diagnosis, thalassemia evaluation, hemoglobin variant identification, prenatal and preconception workflows, HbA1c interference, and confirmatory molecular testing. Regional and country insights were synthesized qualitatively to reflect known disease distribution, migration trends, laboratory access, public health infrastructure, and clinical practice patterns. No market sizing, market share, or forecasting assumptions are included. The methodology emphasizes data-backed interpretation, cross-source validation, clinical plausibility, and careful separation of established evidence from emerging trends such as artificial intelligence-enabled laboratory decision support.

Conclusion

Adult hemoglobinopathy testing is becoming increasingly important as healthcare systems shift toward preventive diagnostics, reproductive risk reduction, precision hematology, and equitable management of inherited blood disorders. The field is moving beyond isolated electrophoresis or chromatography results toward integrated workflows that combine red cell indices, hemoglobin fraction analysis, genetic confirmation, digital reporting, and clinician decision support. Regional needs differ substantially, with Asia-Pacific, the Middle East, and Africa carrying significant inherited disorder burdens, while North America, Europe, Latin America, and Oceania increasingly address migration-linked and ancestry-diverse testing demand. Artificial intelligence, when responsibly validated, can improve case-finding, reporting consistency, and laboratory efficiency, but it must remain anchored in clinical governance and diverse population validation. For industry leaders, the priority is to deliver accurate, accessible, and actionable adult hemoglobinopathy testing that connects diagnosis with counseling, care pathways, and long-term outcomes. The strongest opportunities lie in standardized algorithms, molecular confirmation, interoperable data systems, and inclusive screening strategies that recognize hemoglobinopathy risk as a global health issue rather than a regionally confined condition.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. New Revenue Opportunities
  • 3.5. Next-Generation Business Models
  • 3.6. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Adult Hemoglobinopathy Testing Market, by Modality

  • 7.1. Introduction
  • 7.2. Laboratory Based Tests
    • 7.2.1. Electrophoresis
    • 7.2.2. Genetic Analysis
    • 7.2.3. High Performance Liquid Chromatography
  • 7.3. Point Of Care Tests

8. Adult Hemoglobinopathy Testing Market, by Disease Type

  • 8.1. Introduction
  • 8.2. Hemoglobin C Disease
  • 8.3. Sickle Cell Disease
  • 8.4. Thalassemia
    • 8.4.1. Alpha Thalassemia
    • 8.4.2. Beta Thalassemia
    • 8.4.3. Delta Thalassemia

9. Adult Hemoglobinopathy Testing Market, by Distribution Channel

  • 9.1. Introduction
  • 9.2. Online
  • 9.3. Offline

10. Adult Hemoglobinopathy Testing Market, by End User

  • 10.1. Introduction
  • 10.2. Diagnostic Laboratories
    • 10.2.1. Hospital Laboratories
    • 10.2.2. Independent Laboratories
    • 10.2.3. Reference Laboratories
  • 10.3. Hospitals
    • 10.3.1. Secondary Care Hospitals
    • 10.3.2. Tertiary Care Hospitals
  • 10.4. Research Institutes

11. Adult Hemoglobinopathy Testing Market, by Region

  • 11.1. Asia-Pacific
  • 11.2. Europe
  • 11.3. North America
  • 11.4. Latin America
  • 11.5. Africa
  • 11.6. Middle East

12. Adult Hemoglobinopathy Testing Market, by Group

  • 12.1. NATO
  • 12.2. G7
  • 12.3. BRICS
  • 12.4. European Union
  • 12.5. ASEAN
  • 12.6. GCC

13. Adult Hemoglobinopathy Testing Market, by Country

  • 13.1. China
  • 13.2. United States
  • 13.3. Japan
  • 13.4. India
  • 13.5. Germany
  • 13.6. United Kingdom
  • 13.7. Australia
  • 13.8. France
  • 13.9. South Korea
  • 13.10. Italy
  • 13.11. Canada
  • 13.12. Russia
  • 13.13. Brazil
  • 13.14. Mexico
  • 13.15. Spain

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2025
  • 14.2. FPNV Positioning Matrix, 2025
  • 14.3. Market Concentration Analysis, 2025
    • 14.3.1. Concentration Ratio (CR)
    • 14.3.2. Herfindahl Hirschman Index (HHI)
  • 14.4. Recent Developments & Impact Analysis, 2025
  • 14.5. Product Portfolio Analysis, 2025
  • 14.6. Benchmarking Analysis, 2025

15. Company Profiles

  • 15.1. ARKRAY, Inc.
  • 15.2. Beckman Coulter, Inc.
  • 15.3. Bio-Rad Laboratories, Inc.
  • 15.4. Bluebird Bio, Inc.
  • 15.5. Creative Diagnostics
  • 15.6. F. Hoffmann-La Roche Ltd.
  • 15.7. HORIBA Group
  • 15.8. Illumina, Inc.
  • 15.9. Laboratory Corporation of America Holdings
  • 15.10. Merck KGaA
  • 15.11. PerkinElmer, Inc.
  • 15.12. Quest Diagnostics Incorporated
  • 15.13. Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
  • 15.14. Shimadzu Corporation
  • 15.15. Siemens Healthineers AG
  • 15.16. Sysmex Europe SE
  • 15.17. Thermo Fisher Scientific Inc.
  • 15.18. Tosoh Corporation
  • 15.19. Trinity Biotech PLC

LIST OF FIGURES

  • FIGURE 1. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY MODALITY, 2025 VS 2032 (%)
  • FIGURE 7. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY MODALITY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DISEASE TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DISEASE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 21. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

LIST OF TABLES

  • TABLE 1. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL LABORATORY BASED TESTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL LABORATORY BASED TESTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL LABORATORY BASED TESTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ELECTROPHORESIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ELECTROPHORESIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ELECTROPHORESIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL GENETIC ANALYSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL GENETIC ANALYSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL GENETIC ANALYSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL HIGH PERFORMANCE LIQUID CHROMATOGRAPHY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL HIGH PERFORMANCE LIQUID CHROMATOGRAPHY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL HIGH PERFORMANCE LIQUID CHROMATOGRAPHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL POINT OF CARE TESTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL POINT OF CARE TESTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL POINT OF CARE TESTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL HEMOGLOBIN C DISEASE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL HEMOGLOBIN C DISEASE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL HEMOGLOBIN C DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL SICKLE CELL DISEASE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL SICKLE CELL DISEASE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL SICKLE CELL DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL THALASSEMIA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL THALASSEMIA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL THALASSEMIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ALPHA THALASSEMIA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ALPHA THALASSEMIA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ALPHA THALASSEMIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL BETA THALASSEMIA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL BETA THALASSEMIA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL BETA THALASSEMIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL DELTA THALASSEMIA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL DELTA THALASSEMIA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL DELTA THALASSEMIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ONLINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ONLINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ONLINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL OFFLINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL OFFLINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL OFFLINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL HOSPITAL LABORATORIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL HOSPITAL LABORATORIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL HOSPITAL LABORATORIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL INDEPENDENT LABORATORIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL INDEPENDENT LABORATORIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL INDEPENDENT LABORATORIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL REFERENCE LABORATORIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL REFERENCE LABORATORIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL REFERENCE LABORATORIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL SECONDARY CARE HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL SECONDARY CARE HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL SECONDARY CARE HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL TERTIARY CARE HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL TERTIARY CARE HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL TERTIARY CARE HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. ASIA-PACIFIC ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. ASIA-PACIFIC ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 73. ASIA-PACIFIC ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY LABORATORY BASED TESTS, 2018-2032 (USD MILLION)
  • TABLE 74. ASIA-PACIFIC ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 75. ASIA-PACIFIC ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY THALASSEMIA, 2018-2032 (USD MILLION)
  • TABLE 76. ASIA-PACIFIC ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 77. ASIA-PACIFIC ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 78. ASIA-PACIFIC ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 79. ASIA-PACIFIC ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 80. EUROPE ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. EUROPE ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 82. EUROPE ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY LABORATORY BASED TESTS, 2018-2032 (USD MILLION)
  • TABLE 83. EUROPE ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY THALASSEMIA, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 86. EUROPE ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPE ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 89. NORTH AMERICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY LABORATORY BASED TESTS, 2018-2032 (USD MILLION)
  • TABLE 92. NORTH AMERICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY THALASSEMIA, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 95. NORTH AMERICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. LATIN AMERICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 100. LATIN AMERICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY LABORATORY BASED TESTS, 2018-2032 (USD MILLION)
  • TABLE 101. LATIN AMERICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 102. LATIN AMERICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY THALASSEMIA, 2018-2032 (USD MILLION)
  • TABLE 103. LATIN AMERICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 104. LATIN AMERICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 105. LATIN AMERICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 106. LATIN AMERICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 107. AFRICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. AFRICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 109. AFRICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY LABORATORY BASED TESTS, 2018-2032 (USD MILLION)
  • TABLE 110. AFRICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 111. AFRICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY THALASSEMIA, 2018-2032 (USD MILLION)
  • TABLE 112. AFRICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 113. AFRICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 114. AFRICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 115. AFRICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 116. MIDDLE EAST ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 117. MIDDLE EAST ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 118. MIDDLE EAST ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY LABORATORY BASED TESTS, 2018-2032 (USD MILLION)
  • TABLE 119. MIDDLE EAST ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. MIDDLE EAST ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY THALASSEMIA, 2018-2032 (USD MILLION)
  • TABLE 121. MIDDLE EAST ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 122. MIDDLE EAST ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 123. MIDDLE EAST ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 124. MIDDLE EAST ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. NATO ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 127. NATO ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 128. NATO ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY LABORATORY BASED TESTS, 2018-2032 (USD MILLION)
  • TABLE 129. NATO ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. NATO ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY THALASSEMIA, 2018-2032 (USD MILLION)
  • TABLE 131. NATO ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 132. NATO ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 133. NATO ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 134. NATO ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 135. G7 ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 136. G7 ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 137. G7 ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY LABORATORY BASED TESTS, 2018-2032 (USD MILLION)
  • TABLE 138. G7 ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. G7 ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY THALASSEMIA, 2018-2032 (USD MILLION)
  • TABLE 140. G7 ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 141. G7 ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 142. G7 ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 143. G7 ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 144. BRICS ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 145. BRICS ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 146. BRICS ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY LABORATORY BASED TESTS, 2018-2032 (USD MILLION)
  • TABLE 147. BRICS ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. BRICS ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY THALASSEMIA, 2018-2032 (USD MILLION)
  • TABLE 149. BRICS ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 150. BRICS ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 151. BRICS ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 152. BRICS ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPEAN UNION ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPEAN UNION ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPEAN UNION ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY LABORATORY BASED TESTS, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPEAN UNION ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPEAN UNION ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY THALASSEMIA, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPEAN UNION ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPEAN UNION ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPEAN UNION ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPEAN UNION ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 162. ASEAN ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 163. ASEAN ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 164. ASEAN ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY LABORATORY BASED TESTS, 2018-2032 (USD MILLION)
  • TABLE 165. ASEAN ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. ASEAN ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY THALASSEMIA, 2018-2032 (USD MILLION)
  • TABLE 167. ASEAN ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 168. ASEAN ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 169. ASEAN ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 170. ASEAN ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 171. GCC ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 172. GCC ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 173. GCC ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY LABORATORY BASED TESTS, 2018-2032 (USD MILLION)
  • TABLE 174. GCC ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. GCC ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY THALASSEMIA, 2018-2032 (USD MILLION)
  • TABLE 176. GCC ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 177. GCC ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 178. GCC ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 179. GCC ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 180. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. CHINA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 182. CHINA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 183. CHINA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY LABORATORY BASED TESTS, 2018-2032 (USD MILLION)
  • TABLE 184. CHINA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. CHINA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY THALASSEMIA, 2018-2032 (USD MILLION)
  • TABLE 186. CHINA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 187. CHINA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 188. CHINA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 189. CHINA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 190. UNITED STATES ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 191. UNITED STATES ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 192. UNITED STATES ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY LABORATORY BASED TESTS, 2018-2032 (USD MILLION)
  • TABLE 193. UNITED STATES ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. UNITED STATES ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY THALASSEMIA, 2018-2032 (USD MILLION)
  • TABLE 195. UNITED STATES ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 196. UNITED STATES ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 197. UNITED STATES ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 198. UNITED STATES ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 199. JAPAN ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 200. JAPAN ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 201. JAPAN ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY LABORATORY BASED TESTS, 2018-2032 (USD MILLION)
  • TABLE 202. JAPAN ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 203. JAPAN ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY THALASSEMIA, 2018-2032 (USD MILLION)
  • TABLE 204. JAPAN ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 205. JAPAN ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 206. JAPAN ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 207. JAPAN ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 208. INDIA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 209. INDIA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 210. INDIA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY LABORATORY BASED TESTS, 2018-2032 (USD MILLION)
  • TABLE 211. INDIA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 212. INDIA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY THALASSEMIA, 2018-2032 (USD MILLION)
  • TABLE 213. INDIA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 214. INDIA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 215. INDIA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 216. INDIA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 217. GERMANY ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 218. GERMANY ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 219. GERMANY ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY LABORATORY BASED TESTS, 2018-2032 (USD MILLION)
  • TABLE 220. GERMANY ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 221. GERMANY ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY THALASSEMIA, 2018-2032 (USD MILLION)
  • TABLE 222. GERMANY ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 223. GERMANY ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 224. GERMANY ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 225. GERMANY ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 226. UNITED KINGDOM ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 227. UNITED KINGDOM ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 228. UNITED KINGDOM ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY LABORATORY BASED TESTS, 2018-2032 (USD MILLION)
  • TABLE 229. UNITED KINGDOM ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 230. UNITED KINGDOM ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY THALASSEMIA, 2018-2032 (USD MILLION)
  • TABLE 231. UNITED KINGDOM ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 232. UNITED KINGDOM ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 233. UNITED KINGDOM ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 234. UNITED KINGDOM ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 235. AUSTRALIA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 236. AUSTRALIA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 237. AUSTRALIA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY LABORATORY BASED TESTS, 2018-2032 (USD MILLION)
  • TABLE 238. AUSTRALIA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 239. AUSTRALIA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY THALASSEMIA, 2018-2032 (USD MILLION)
  • TABLE 240. AUSTRALIA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 241. AUSTRALIA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 242. AUSTRALIA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 243. AUSTRALIA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 244. FRANCE ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 245. FRANCE ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 246. FRANCE ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY LABORATORY BASED TESTS, 2018-2032 (USD MILLION)
  • TABLE 247. FRANCE ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 248. FRANCE ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY THALASSEMIA, 2018-2032 (USD MILLION)
  • TABLE 249. FRANCE ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 250. FRANCE ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 251. FRANCE ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 252. FRANCE ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 253. SOUTH KOREA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 254. SOUTH KOREA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 255. SOUTH KOREA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY LABORATORY BASED TESTS, 2018-2032 (USD MILLION)
  • TABLE 256. SOUTH KOREA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 257. SOUTH KOREA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY THALASSEMIA, 2018-2032 (USD MILLION)
  • TABLE 258. SOUTH KOREA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 259. SOUTH KOREA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 260. SOUTH KOREA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 261. SOUTH KOREA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 262. ITALY ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 263. ITALY ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 264. ITALY ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY LABORATORY BASED TESTS, 2018-2032 (USD MILLION)
  • TABLE 265. ITALY ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 266. ITALY ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY THALASSEMIA, 2018-2032 (USD MILLION)
  • TABLE 267. ITALY ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 268. ITALY ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 269. ITALY ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 270. ITALY ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 271. CANADA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 272. CANADA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 273. CANADA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY LABORATORY BASED TESTS, 2018-2032 (USD MILLION)
  • TABLE 274. CANADA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 275. CANADA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY THALASSEMIA, 2018-2032 (USD MILLION)
  • TABLE 276. CANADA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 277. CANADA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 278. CANADA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 279. CANADA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 280. RUSSIA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 281. RUSSIA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 282. RUSSIA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY LABORATORY BASED TESTS, 2018-2032 (USD MILLION)
  • TABLE 283. RUSSIA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 284. RUSSIA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY THALASSEMIA, 2018-2032 (USD MILLION)
  • TABLE 285. RUSSIA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 286. RUSSIA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 287. RUSSIA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 288. RUSSIA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 289. BRAZIL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 290. BRAZIL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 291. BRAZIL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY LABORATORY BASED TESTS, 2018-2032 (USD MILLION)
  • TABLE 292. BRAZIL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 293. BRAZIL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY THALASSEMIA, 2018-2032 (USD MILLION)
  • TABLE 294. BRAZIL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 295. BRAZIL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 296. BRAZIL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 297. BRAZIL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 298. MEXICO ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 299. MEXICO ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 300. MEXICO ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY LABORATORY BASED TESTS, 2018-2032 (USD MILLION)
  • TABLE 301. MEXICO ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 302. MEXICO ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY THALASSEMIA, 2018-2032 (USD MILLION)
  • TABLE 303. MEXICO ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 304. MEXICO ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 305. MEXICO ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 306. MEXICO ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 307. SPAIN ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 308. SPAIN ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 309. SPAIN ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY LABORATORY BASED TESTS, 2018-2032 (USD MILLION)
  • TABLE 310. SPAIN ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 311. SPAIN ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY THALASSEMIA, 2018-2032 (USD MILLION)
  • TABLE 312. SPAIN ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 313. SPAIN ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 314. SPAIN ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 315. SPAIN ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 316. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SHARE, BY KEY PLAYER, 2025
  • TABLE 317. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025